Interaction Checker

Interaksi Pazopanib

Pazopanib (Votrient) memiliki 257 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 148 mayor, 107 moderat, 2 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (148)

  • Abrositinibpenghambat JAKMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • Alfuzosinpenyekat alfaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • AmiodaronantiaritmiaMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Amitriptilinantidepresan trisiklikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Anagrelidobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Antasida (Tums, Maalox, Mylanta)Produk obat bebasMayor

    If concomitant administration with a gastric acid-reducing agent cannot be avoided, consider short-acting antacids in place of PPIs and H2-receptor antagonists. (label Pazopanib, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Arsen trioksidaobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • AsenapinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • AtazanavirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Azitromisinantibiotik makrolidaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • DarunavirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Dekslansoprazolpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Dekstrometorfan dan kuinidinobat serotonergikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Deutetrabenazinpenghambat VMAT2Mayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • DisopiramidantiaritmiaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • DofetilidantiaritmiaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • DronedaronantiaritmiaMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Droperidolantagonis dopaminMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • EfavirenzantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Elvitegravir, kobisistat, emtrisitabin, dan tenofovirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Eritromisinantibiotik makrolidaMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • EsitalopramSSRIMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Esomeprazolpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • EtravirinantiretroviralMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • EverolimusimunosupresanMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Famotidinpenghambat H2Mayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • FingolimodimunosupresanMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • FlekainidantiaritmiaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Flibanserindepresan SSPMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • Flukonazolantijamur azolMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • FluoksetinSSRIMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • FosamprenavirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Granisetronobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • GriseofulvinantijamurMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • HaloperidolantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Hidroksiklorokuinobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • HidroksizinantihistaminMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Ibuprofen dan famotidinOAINSMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • IbutilidantiaritmiaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • IloperidonantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Imatinibpenghambat CYP3A4Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • IsoniazidantibiotikMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Itrakonazolantijamur azolMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Ketokonazolantijamur azolMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Klaritromisinantibiotik makrolidaMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • KlobazambenzodiazepinMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • KlorokuinantimalariaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • KlorpromazinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • KlozapinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • KuetiapinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • KuinidinantiaritmiaMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • KuininantimalariaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Lansoprazolpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Lapatinibpenghambat P-glikoproteinMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • Ledipasvir dan sofosbuvirantivirusMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • LenakapavirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • LevofloksasinfluorokuinolonMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Loperamidobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • MetadonopioidMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Mirabegronagonis beta-adrenergikMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • MoksifloksasinfluorokuinolonMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Naproksen dan esomeprazolOAINSMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Natrium bikarbonatantasidaMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • NefazodonantidepresanMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • NevirapinantiretroviralMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Nilotinibobat yang memperpanjang interval QTMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Nizatidinpenghambat H2Mayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • OfloksasinfluorokuinolonMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Olanzapin dan fluoksetinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Omeprazolpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Omeprazol dan natrium bikarbonatpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Ondansetronobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • PaliperidonantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Pantoprazolpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Pentamidinobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • PerampanelantikonvulsanMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • PimavanserinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • PimozidantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Pitolisantobat yang memperpanjang interval QTMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Posakonazolantijamur azolMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • PrimidonantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • ProkainamidantiaritmiaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • PrometazinantihistaminMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Prometazin dan dekstrometorfanantihistaminMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Prometazin dan kodeinopioidMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • PropafenonantiaritmiaMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • Rabeprazolpenghambat pompa protonMayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Ranitidinpenghambat H2Mayor

    Concomitant Use With Gastric Acid-Reducing Agents : Avoid concomitant use of VOTRIENT with gastric acid-reducing agents. (label Pazopanib, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • RifabutinantibiotikMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • RifampisinantibiotikMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • RifapentinantibiotikMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • RisperidonantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • RitonavirantiretroviralMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • SiklosporinimunosupresanMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • SiprofloksasinfluorokuinolonMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • SitalopramSSRIMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Sofosbuvir dan velpatasvirantivirusMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

  • SolifenasinantikolinergikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Sotalolpenyekat betaMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Suvoreksantsedatif-hipnotikMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • TakrolimusimunosupresanMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Tamoksifenmodulator reseptor estrogen selektifMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Tetrabenazinpenghambat VMAT2Mayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • TikagrelorantiplateletMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • TioridazinantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • TolterodinantikolinergikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    VOTRIENT is not recommended if chronic use of strong CYP3A4 inducers cannot be avoided. (label Pazopanib, Interaksi obat)

  • Toremifenmodulator reseptor estrogen selektifMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • TramadolopioidMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Tramadol dan parasetamolopioidMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • TrazodonantidepresanMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Valbenazinpenghambat VMAT2Mayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Vardenafilpenghambat PDE5Mayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • VenlafaksinSNRIMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • Vorikonazolantijamur azolMayor

    Strong CYP3A4 Inhibitors : Avoid coadministration of VOTRIENT with strong CYP3A4 inhibitors. (label Pazopanib, Interaksi obat)

  • ZiprasidonantipsikotikMayor

    Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (label Pazopanib, Interaksi obat)

  • ZonisamidantikonvulsanMayor

    Avoid concomitant use of VOTRIENT with strong inhibitors of P-gp or BCRP. (label Pazopanib, Interaksi obat)

Interaksi moderat (107)

  • AdenosinantiaritmiaModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • AliskirenantihipertensiModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Amiloriddiuretik hemat kaliumModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Amlodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Amlodipin dan atorvastatinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Amlodipin dan benazeprilpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Amlodipin dan olmesartanpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Amlodipin dan valsartanpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Asam etakrinatdiuretik loopModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Asebutololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Atenololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Atenolol dan klortalidonpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • AtorvastatinstatinModerat

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (label Pazopanib, Peringatan dan perhatian)

  • Azilsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Benazeprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Benazepril dan hidroklorotiazidpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Betaksololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Bisoprololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Bisoprolol dan hidroklorotiazidpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Digoksinglikosida digitalisModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • Doksazosinpenyekat alfaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Enalapril dan hidroklorotiazidpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Enalaprilatpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Eplerenonantagonis aldosteronModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Esmololpenyekat betaModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • Ezetimib dan simvastatinstatinModerat

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (label Pazopanib, Peringatan dan perhatian)

  • Felodipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Fenoksibenzaminpenyekat alfaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • FluvastatinstatinModerat

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (label Pazopanib, Peringatan dan perhatian)

  • Fosinoprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Fosinopril dan hidroklorotiazidpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Furosemiddiuretik loopModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Guanfasinagonis alfa-adrenergikModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • HidralazinvasodilatorModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Hidroklorotiaziddiuretik tiazidModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Indapamiddiuretik tiazidModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Irbesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Irbesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Isosorbid dinitrat dan hidralazinnitratModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Isradipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Kandesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Kandesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Kaptoprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Karvedilolpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Klonidinagonis alfa-adrenergikModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Klorotiaziddiuretik tiazidModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Klortalidondiuretik tiazidModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Kuinaprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Kuinapril dan hidroklorotiazidpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Labetalolpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Levotiroksinhormon tiroidModerat

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Levotiroksin dan liotironinhormon tiroidModerat

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Lidokainanestetik lokalModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • Lidokain dan prilokainanestetik lokalModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • Liotironinhormon tiroidModerat

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Lofeksidinagonis alfa-adrenergikModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • LomitapidModerat

    …Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology (12.3) ] . (label Lomitapid, Interaksi obat)

  • Losartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Losartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • LovastatinstatinModerat

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (label Pazopanib, Peringatan dan perhatian)

  • MekamilaminantihipertensiModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • MeksiletinantiaritmiaModerat

    Monitor patients who are at significant risk of developing QTc prolongation, including patients with a history of QT interval prolongation, in patients taking antiarrhythmics or other medications that may prolong QT interval, and those with relevant preexisting cardiac disease [see Drug Interactions (7.5)] . (label Pazopanib, Peringatan dan perhatian)

  • MetildopaantihipertensiModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Metolazondiuretik tiazidModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Metoprololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Metoprolol dan hidroklorotiazidpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • MinoksidilvasodilatorModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Moeksiprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Nadololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Nebivololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Nifedipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Nikardipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Nisoldipinpenghambat kanal kalsium dihidropiridinModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • NitroprusidvasodilatorModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Olmesartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Olmesartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Olmesartan, amlodipin, dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • PemetreksedantimetabolitModerat

    Clinical trials of VOTRIENT in combination with pemetrexed and lapatinib were terminated early due to increased toxicity and mortality. (label Pazopanib, Peringatan dan perhatian)

  • Perindoprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Pindololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • PitavastatinstatinModerat

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (label Pazopanib, Peringatan dan perhatian)

  • PravastatinstatinModerat

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (label Pazopanib, Peringatan dan perhatian)

  • Prazosinpenyekat alfaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Propiltiourasilobat antitiroidModerat

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Propranololpenyekat betaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Ramiprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • RosuvastatinstatinModerat

    Insufficient data are available to assess the risk of concomitant administration of alternative statins and VOTRIENT. (label Pazopanib, Peringatan dan perhatian)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • SimvastatinstatinModerat

    Concomitant Use of Simvastatin Concomitant use of VOTRIENT and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)] . (label Pazopanib, Peringatan dan perhatian)

  • Spironolaktonantagonis aldosteronModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Spironolakton dan hidroklorotiazidantagonis aldosteronModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Telmisartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Telmisartan dan amlodipinpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Telmisartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Terazosinpenyekat alfaModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Teriparatidhormon tiroidModerat

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Tiamazolobat antitiroidModerat

    Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Tizanidinpelemas ototModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Torasemiddiuretik loopModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Triamterendiuretik hemat kaliumModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Triamteren dan hidroklorotiaziddiuretik hemat kaliumModerat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Valsartanpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

  • Valsartan dan hidroklorotiazidpenghambat reseptor angiotensin II (ARB)Moderat

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

Penyebutan minor (2)

  • BevasizumabMinor

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (label Pazopanib, Peringatan dan perhatian)

  • TopotekanMinor

    Thrombotic Microangiopathy Thrombotic microangiopathy (TMA), including thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), occurred in clinical trials of VOTRIENT as monotherapy, in combination with bevacizumab, and in combination with topotecan. (label Pazopanib, Peringatan dan perhatian)

Periksa Pazopanib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.